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Abstract 
HMGN5 is a member of the high mobility group 
nucleosome binding domain (HMGN) protein 
family. HMGN proteins are ubiquitously expressed 
in vertebrate cells. They are nuclear proteins that 
bind specifically to nucleosomes without specificity 
for the DNA sequence and affect the structure and 
function of chromatin. HMGN5 sequences have 
been detected in all vertebrate tissues examines. 
HMGN5 differs from the other members of the 
HMGN family in that it is significantly larger and its 
amino acid sequence varies significantly between 
different vertebrate species. 
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Identity 
Other names: NSBP1, NBP-45 
HGNC (Hugo): HMGN5 
Location (base pair): Starts at 81113701 and ends 
at 81201942 bp from pter (according to NCBI 11-
Apr_2016) 
Reproduced from: HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. 
Rochman M, Malicet C, Bustin M. Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. 
Review. PMID: 20123071
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Organization of the human HMGN5 and mouse Hmgn5 gene. Exons are marked by red blocks and untranslated regions are 
marked by white boxes. The number of amino acids encoded by each exon is indicated. Reproduced from: HMGN5/NSBP1: a 
new member of the HMGN protein family that affects chromatin structure and function. Rochman M, Malicet C, Bustin M. 
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. Review. PMID: 20123071 
 
 
DNA/RNA 
Description 
NCBI Reference Sequence: NC_000023.11; Coding 
positions from 81,113,701 to 81,201,942 (length: 
88,242 bp). Both human and mouse Hmgn5 genes 
are composed of 6 exons and 5 introns. 
Transcription 
849 bp cDNA for Human HMGN5. No splicing 
isoforms are reported as of April 2016. 
Protein 
Description 
Reference sequence for HMGN5 protein: 
NP_110390.1. HMGN5 contains 282 amino acid  
residues with a molecular weight of 31525 Da. 
HMGN5 belongs to the HMGN protein family. 
HMGN5 contains a Nucleosome Bingding Domain 
(residue 12-36) for chromatin interaction. 
Expression 
Expressed at low levels in most vertebrate cells. 
Localisation 
Nucleus. 
Function 
Modulates chromatin structure. 
Homology 
HomoloGene (NCBI) Genes identified as putative 
homologs: NP_110390.1 HMGN5, Homo sapiens; 
XP_001144951.2 Hmgn5, Pan troglodytes; 
XP_001103630 Hmgn5 Macaca mulatta; 
XP_002699982.3 Hmgn5, Bos taurus. 
 
 
Schematic representation of structural domains of mouse and human HMGN5 proteins. Localization of each domain is related to 
the amino acid sequences of the proteins numbered on top of each scheme. Reproduced from: HMGN5/NSBP1: a new member 
of the HMGN protein family that affects chromatin structure and function. Rochman M, Malicet C, Bustin M. Biochim Biophys 
Acta. 2010 Jan-Feb;1799(1-2):86-92. doi: 0.1016/j.bbagrm.2009.09.012. Review. PMID: 20123071 
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Implicated in 
Clear cell renal cell carcinoma 
(ccRCC) 
HMGN5 expression is detected in renal tissues from 
clear cell renal cell carcinoma (ccRCC) patients and 
in ccRCC cell lines, and its expression level is 
associated with tumor grade.  
Knockdown of HMGN5 induced cell cycle arrest 
and apoptosis, and inhibited invasion in ccRCC cell 
line 786-O. (Ji et al, 2012). 
Prostate Cancer 
Knock down of HMGN5 inhibits the in vitro and in 
vivo growth of the human prostate cancer cell line 
DU145 by inducing cell cycle arrest and apoptosis 
(Jiang et al, 2010). Similar effect is also observed in 
the LNCaP prostate cancer cell line, too (Zhang et al, 
2012).  
HMGN5 knockdown exhibit increased apoptosis 
rate in response to ionizing radiation (Su et al, 2015). 
The normal prostate epithelial cells which are 
induced Ectopic HMGN5 expression results in 
oncogenic phenotype such as colony formation and 
invasion (Guo et al, 2015).  
Tumorigenic activity of the cells which overexpress 
HMGN5 is suppressed by MIR340 (microRNA-340) 
(Wei et al, 2015). 
Gliomas 
HMGN5 is highly expressed in both low-grade and 
high-grade glioma tissue samples than normal brain 
tissues.  
The down regulation of HMGN5 expression in 
human glioma cell line (U251 and U87) caused cell 
cycle arrest and apoptosis. (Qu et al, 2011). 
Bladder cancer 
The protein level of HMGN5 in surgically removed 
bladder cancer specimens and human bladder cell 
lines is correlated with the increased tumor grade and 
pathologic stage.  
Knock down of HMGN5 reduced cell viability and 
cell cycle promotion (Wahafu et al, 2010; Gan et al, 
2015).  
The expression level of HMGN5 is suppressed by 
MIR186 in human bladder cancer cells (Yao et al, 
2015). 
Lung cancer 
HMGN5 is highly expressed in lung cancer cell lines 
A549 and H1299. Downregulation of HMGN5 
inhibits cell proliferation and colony formation 
(Chen et al, 2012).  
MIR326 downregulated HMGN5 expression in the 
non-small cell lung cancer (NSCLC) cell and 
inhibited cell proliferation and invasion of NSCLC 
(Li et al, 2016). 
Osteosarcoma 
Both HMGN5 RNA and HMGN5 protein are highly 
expressed in human osteosarcoma tumor. The 
expression level is also upregulated in osteosarcoma 
cell lines SaO2 and HOS while other cell lines U-
2OS and MG63 showed lower expression level. 
HMGN5 expression is induced by anticancer agents 
in these cell lines. Overexpression of HMGN5 in U-
2OS and MG63 cells increased drug resistance by 
upregulating autophagy (Yang et al, 2014). 
Breast cancer 
HMGN5 is highly expressed in breast cancer tissues 
when compared with the adjacent non-cancerous 
tissues. Clinical and histopathologic analysis 
revealed that HMGN5 expression level is correlated 
to the tumor grade and staging. Using the human 
breast cancer cell line MCA-MB-213 as a model, 
HMGN5 knockdown resulted in inhibition of 
migration and invasion, and induced cell death 
(Weng et al, 2015). 
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